June 6 (NBD) -- Chinese manufacturer of antibiotics Huadong Medicine Co., Ltd (000963.SZ) said on Monday that the market share of the company's Acarbose tablets "Kaboping" surpassed half of that secured by the original manufacturer Bayer AG's "Glucobay".

Huadong Medicine has a track record of 15 years' experience in manufacturing Acarbose tablets and its advantages in technology, sales and scale development will help narrow the gap of Acarbose market share between the company and Bayer AG, noted Huadong Medicine.

According to a report by Minsheng Securities, the market of Acarbose tablets, a prescription drug for non-insulin dependent diabetes, is projected to reach 14.8 billion yuan (2.3 billion U.S. dollars) and "Kaboping" of Huadong Medicine has the opportunity to reap approximately 5 billion yuan (780.8 million U.S. dollars).

Email: gaohan@nbd.com.cn